Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of sunitinib on VEGF and interleukin-8 expression in metastatic renal cell carcinoma
2008-004137-21Phase 3Active
- Sponsor
- Centre Antoine Lacassagne
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sunitinib in metastatic renal cell carcinoma (mRCC), sponsored by Centre Antoine Lacassagne. Primary endpoint: Tumor response per RECIST and correlation with VEGF and IL-8. Started Mar 2009; status: active.
02
Drugs
sunitinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2008-004137-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004137-21.